Clinical Trials Directory

Trials / Completed

CompletedNCT00507169

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
—
Sponsor
Salvat · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Conditions

Interventions

TypeNameDescription
DRUGSVT-40776

Timeline

Start date
2006-09-01
Primary completion
2007-09-01
Completion
2007-09-01
First posted
2007-07-26
Last updated
2011-06-08

Source: ClinicalTrials.gov record NCT00507169. Inclusion in this directory is not an endorsement.

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome (NCT00507169) · Clinical Trials Directory